General anesthetics is one of the major classes of drugs used for general anesthesia. General anesthetics can be administered for a number of medical conditions including but not limited to the following: respiratory problems, such as lung cancer and asthma; cardiac problems, such as congenital heart disease and myocardial infarction; neurological disorders, such as seizures and Parkinson's disease; severe burns and traumatic brain injury. General anesthesia can also be given for cosmetic reasons, such as breast augmentation and nose surgery.
Market Dynamics:
Increasing funding for R&D in anesthetic drugs is expected to propel growth of the general anesthesia drugs market over the forecast period. For instance, in August 2021, researchers at Washington University School of Medicine in St. Louis and the University of Michigan received a US$ 33 million grant from the Patient-Centered Outcomes Research Institute to compare intravenous propofol to inhaled anesthetic drugs to determine which of the common anesthetic drugs offers better patient recovery experiences and improved clinical outcomes.
Product recall is expected to limit growth of the general anesthesia drugs market over the forecast period. For instance, in May 2021, Hospira announced to recall one lot each of the injectable hospital anesthetics bupivacaine HCL and lidocaine HCL due to mislabeling of product.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook